NOVARTIS INDIA LIMITED
NOVARTIND · General/Diversified · NSE
₹989
Current Market Price
Fair Value (DCF)
₹675
Margin of Safety
-31.7%
Updated 18h ago
YieldIQ Score
56/100
Piotroski F-Score
8/9
Economic Moat
Wide
Confidence
74%
ROE
—
Debt/Equity
0.01
WACC
11.1%
Market Cap
₹2,442 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
16.3%
Return on capital employed
EV / EBITDA
20.1×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
170.4×
EBIT covers interest
Current Ratio
5.25×
Short-term liquidity
Asset Turnover
0.38×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-2.8%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹988.9
Bear case
₹370.01
MoS -167.3%
Base case
₹675.31
MoS -46.4%
Bull case
₹767.46
MoS -28.9%
Ratio Trends
NOVARTIND · last 4 annual periods
ROE
12.9%
ROCE
16.9%
Operating Margin
—
Debt / Equity
0.01×
PE
13.5×
EV / EBITDA
11.3×
Historical Financials
NOVARTIND · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹388 Cr | ₹369 Cr | ₹334 Cr | ₹356 Cr | -2.8% |
| EBITDA | ₹10.7 Cr | ₹123 Cr | ₹127 Cr | ₹133 Cr | +132.2% |
| EBIT | — | — | — | — | — |
| PAT | ₹-3.7 Cr | ₹103 Cr | ₹85.2 Cr | ₹101 Cr | — |
| EPS (diluted) | — | — | — | — | — |
| CFO | ₹38.7 Cr | ₹44.8 Cr | ₹113 Cr | ₹74.6 Cr | +24.5% |
| CapEx | ₹-0.5 Cr | ₹-0.3 Cr | — | — | — |
| FCF | ₹38.2 Cr | ₹44.5 Cr | — | — | +5.2% |
| Total Assets | ₹958 Cr | ₹983 Cr | ₹925 Cr | ₹948 Cr | -0.3% |
| Total Debt | ₹24.0 Cr | ₹21.5 Cr | ₹7.0 Cr | ₹5.1 Cr | -40.5% |
| Shareholders' Equity | ₹692 Cr | ₹776 Cr | ₹745 Cr | ₹785 Cr | +4.3% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
NOVARTIND vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| SIMPLEXINF SIMPLEXINF | — | — | Pending | 2.2% | — |
| ADOR ADOR | — | — | Pending | 11.8% | — |
| INDIANHUME INDIANHUME | — | — | Pending | 40.5% | — |
| CONFIPET CONFIPET | — | — | Pending | 6.0% | — |
| COSMOFIRST COSMO FIRST LIMITED | -25.0% | 28 | Overvalued | 9.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for NOVARTIND in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Novartis India Limited has a current price of 988.90 and a fair value of 675.31, with a ROCE of 16.3% and debt-to-equity ratio of 0.01. I...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of NOVARTIND →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for NOVARTIND →
Compare
Head-to-head with peers
Compare NOVARTIND side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse NOVARTINDNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.